91 results about "Staphylococcus aureus infections" patented technology

The invention provides a thiazolidinone compound and application thereof in preparation of drugs for resisting staphylococcus aureus infection. The molecular structural formula of the thiazolidinone compound is shown as a formula (1), a formula (2), a formula (3) or a formula (4). The technical scheme of the invention discloses several thiazolidinone compounds, which not only have an excellent bactericidal effect on staphylococcus aureus and can significantly inhibit the formation of a biofilm of staphylococcus aureus, but also have low cytotoxicity and hemolytic activity. According to the technical scheme, a certain foundation is laid for research and development of novel staphylococcus aureus biofilm infection resisting drugs, and the potential of thiazolidone derivatives for developing novel antibacterial agents for staphylococcus aureus related infection can be deeply known possibly.

The invention relates to the technical field of biological medicine, in particular to an antibody aiming at staphylococcus aureus enterotoxin B and application thereof. A heavy chain variable region of the antibody provided by the invention comprises CDR sequences as shown in SEQ ID NO.1-3, and a light chain variable region of the antibody comprises CDR sequences as shown in SEQ ID NO.9-11. The antibody has high affinity, can specifically bind to staphylococcus aureus SEB, can block binding of SEB and MHC II / TCR, significantly inhibits cytokine storm, shows a dose-dependent protection effect in an MRSA systemic infection model, and can be used for preparing an MRSA systemic infection model. The monoclonal antibody can be used for treating, preventing or diagnosing the infection of the staphylococcus aureus, provides a solution of non-antibiotic therapy for SEB poisoning and drug-resistant staphylococcus aureus infection, and has important clinical and public health values.

The invention discloses an application of an Mxene-Mo4VC4 new member nano platform with light-enhanced peroxidase activity in treatment of methicillin-resistant staphylococcus aureus infection so as to promote healing of infected wounds, and belongs to the field of two-dimensional nano material catalyst antibacterial research. The single-layer Mo4VC4 nanosheet is synthesized on the basis of Mo4AlVC4-MXene through a hydrofluoric acid etching method. The Mo4VC4 nanosheet shows activity similar to peroxidase, and can locally catalyze low-concentration hydrogen peroxide and generate hydroxyl radicals toxic to bacteria, so that methicillin-resistant staphylococcus aureus is effectively killed, and a biological membrane is removed. In addition, high photo-thermal conversion efficiency and photo-thermal stability are shown under irradiation of near-infrared light with low concentration (50 mu g / mL). The similar peroxidase activity is obviously amplified by the temperature rise caused by the photothermal effect of the Mo4VC4 nanosheet. And finally, rapidly eliminating methicillin-resistant staphylococcus aureus in deep infection and accelerating abscess regression by adopting a satisfactory photo-thermal amplification peroxidase strategy.

The invention discloses application of fludarabine in treatment of methicillin-resistant staphylococcus aureus infection, and in an MRSA infected mouse model, it is verified that fludarabine can improve the survival rate of MRSA infected mice, reduce the MRSA bacterial count of lungs, livers, spleens and kidneys and relieve the injury degree of lungs, livers, spleens and kidneys caused by MRSA infection; pSMalpha3 is found to be an important virulence factor of MRSA, is closely related to high pathogenicity of MRSA, and can induce death of macrophages in a concentration-dependent manner, and fludarabine can significantly reduce cytotoxicity caused by PSMalpha3.

The invention discloses an application of a compound 5928-0054 in preparation of anti-staphylococcus aureus hemolysin medicines, and belongs to the field of microbial infectious diseases and medicines. The invention finds that the compound 5928-0054 can neutralize the toxicity of staphylococcus aureus hemolysin, has a protection effect on mice infected by MRSA staphylococcus aureus USA300, and has the application of preparing the anti-staphylococcus aureus hemolysin medicine and the medicine for preventing or treating staphylococcus aureus infection. The new medicinal value of the compound 5928-0054 is found, and a new medicine for preventing and treating staphylococcus aureus infection is provided; the compound 5928-0054 can neutralize the main virulence factor of staphylococcus aureus, namely hemolysin, so that inflammatory injury is relieved.

This invention discloses the application of ferrous ions in the preparation of products for treating bacterial infections, belonging to the field of pharmaceutical technology. Antibacterial activity tests of ferrous ions against Staphylococcus aureus showed strong bactericidal effects, with a survival rate of less than 0.001% against Staphylococcus aureus and less than 0.01% against methicillin-resistant Staphylococcus aureus (MRSA). The use of ferrous ion-containing hydrogels in the treatment of keratitis and skin wound infections significantly reduced the risk of MRSA infection in the lungs and effectively prevented the proliferation and spread of microorganisms in the body, revealing that drugs containing ferrous compounds can be used to treat Staphylococcus aureus infections, including MRSA.

The invention is applicable to the technical field of genetic engineering, and provides a vaccine for preventing and treating staphylococcus aureus mastitis and application of the vaccine. A recombinant bacillus subtilis construction method comprises the following steps: taking a DNA sequence as shown in SEQ ID NO.3 as a template, and performing PCR amplification to obtain a PCR product sequence; connecting the PCR product to a pHT43 vector, and converting the pHT43 vector into a competent cell DH5alpha, so as to obtain a recombinant plasmid pHT43-cCsa; the method comprises the following steps: transforming a recombinant plasmid pHT43-cCsa into a competent cell of bacillus subtilis WB800N, taking pHT43-F and pHT43-R as primers, and screening a positive transformant through a PCR (Polymerase Chain Reaction) technology; the recombinant bacillus subtilis for expressing the staphylococcus aureus Csa protein is constructed by utilizing a homologous recombination technology, so that pathological injury caused by staphylococcus aureus infection can be reduced, and staphylococcus aureus mastitis of dairy cattle can be prevented.

The invention discloses antibiotic-free hydrogel for nursing staphylococcus aureus infection as well as a preparation method and application of the antibiotic-free hydrogel. The hydrogel is prepared from metal ion compounds such as zinc ions, copper ions and iron ion compounds, a natural high polymer material and an antioxidant as raw materials, and has the advantages of efficient antibacterial property, high safety, long-acting slow release and the like. An in-vitro antibacterial experiment shows that the sterilizing rate of the metal ion compound on staphylococcus aureus can reach 90%-99.9%; animal experiments prove that the hydrogel can effectively relieve inflammatory reaction of infected parts, and skin irritation experiments show that the product is free of irritation and anaphylactic reaction. The invention provides a safe and effective nonreactive solution for nursing of staphylococcus aureus infection.

The application belongs to the field of antibacterial two-dimensional nanomaterial Mxene catalysts, and particularly relates to a monolayer W@MoS2 nanosheet as well as a preparation method and application thereof. The method comprises the following steps: 1) dissolving water-soluble molybdate and water-soluble tungstate in water to obtain a mixed solution; 2) adding a sulfur source and an organic solvent to the mixed solution, and then performing reaction after mixing, and drying to obtain a powder. The monolayer W@MoS2 nanosheet has a unique two-dimensional planar structure, a large specific surface area, and good optical and electronic properties, and has high light-heat absorption in the near-infrared two region, i.e., the light-heat conversion efficiency is improved. Meanwhile, the peroxidase-like activity of the monolayer W@MoS2 nanosheet material realizes efficient light-heat amplification, can treat methicillin-resistant Staphylococcus aureus infection, and avoids heat therapy damage to normal tissues.

The invention relates to the technical field of medicine synthesis, and particularly discloses an aminoguanidine tetralone derivative and a structural general formula of the aminoguanidine tetralone derivative. The invention also discloses a preparation method and application of the derivative. The aminoguanidine tetralone derivative has a good inhibiting and killing effect on staphylococcus aureus and can be used for preventing and treating diseases caused by staphylococcus aureus infection.

The invention relates to a PPP2CB phosphatase target small molecule compound and application thereof, and belongs to the field of biological medicine. The invention provides a small molecule compound C16H16N4O, which is specifically combined with a PPP2CB catalytic subunit, and by enhancing the activity of PPP2CB phosphatase, the serine / threonine phosphorylation level of ERK, MAPK, JAK and other kinases in macrophages is remarkably reduced, and the activation of NF-kappa B, JAK-STAT and MAPK-ERK inflammation signal pathways is blocked. The compound is suitable for treating inflammatory storm caused by SARS-CoV-2, influenza virus and staphylococcus aureus infection. In an SARS-CoV-2 infection model, the survival rate of the mice is increased from 0 to 50%; the lung pathological injury is relieved after influenza virus infection. Sepsis caused by staphylococcus aureus USA300 is effectively inhibited, and the death rate is reduced. The clinical transformation potential is realized.

The present invention relates to a series of cell wall degrading enzymes with antibacterial activity for effectively controlling Staphylococcus aureus, and the cell wall degrading enzymes with antibacterial activity of the present invention are a series of lyases with new amino acid sequences. The cell wall degrading enzymes with antibacterial activity of the present invention can be used as agents capable of effectively inhibiting Staphylococcus aureus, and can be applied to the disinfection of Staphylococcus aureus in the environment and the treatment of diseases caused by Staphylococcus aureus infection, etc.

The present invention discloses an mRNA encoding an anti-Staphylococcus aureus enterotoxin B antibody and an application thereof. The mRNA comprises an mRNA encoding a light chain of the anti-Staphylococcus aureus enterotoxin B antibody and an mRNA encoding a heavy chain of the anti-Staphylococcus aureus enterotoxin B antibody, wherein the optimized base sequences of the variable regions CDR1, CDR2 and CDR3 of the heavy chain are shown as SEQ ID NO.4, SEQ ID NO.5 and SEQ ID NO.6, respectively; and the optimized base sequences of the variable regions CDR1, CDR2 and CDR3 of the light chain are shown as SEQ ID NO.7, SEQ ID NO.8 and SEQ ID NO.9. The antibody can be used to neutralize SEB toxin and simultaneously prevent and treat Staphylococcus aureus infection.

The present invention discloses four quaternary ammonium salt derivatives, their synthesis methods, and applications. One quaternary ammonium salt derivative of the present invention has the chemical name (E)-N,N,N-trimethyl-1-(4-(phenyldiazenyl)phenyl)methylammonium bromide (Compound 1e). Compound 1e, synthesized using aniline as a starting material, exhibits excellent antibacterial activity against Staphylococcus aureus at 500 μg / mL.

The application discloses an antibody against Staphylococcus aureus IsdB and application thereof. The antibody comprises a heavy chain variable region and a light chain variable region, the amino acid sequences of CDR1, CDR2 and CDR3 of the heavy chain variable region are respectively shown as SEQ ID NO:1, SEQ ID NO:2 and SEQ ID NO:3, and the amino acid sequences of CDR1, CDR2 and CDR3 of the light chain variable region are respectively shown as SEQ ID NO:9, SEQ ID NO:10 and SEQ ID NO:11. In addition, the application further discloses a product for detecting Staphylococcus aureus IsdB and application of the antibody in preparation of a diagnosis, prevention and / or treatment of diseases related to Staphylococcus aureus infection. The application provides a new idea for detection of Staphylococcus aureus IsdB and treatment of related diseases, and has a wide application prospect.

The invention provides an application of SX-682 in preparation of a drug for resisting staphylococcus aureus infection, and the SX-682 has a CAS number of 1648843-04-2. According to the technical scheme, the novel medical application of the SX-682 is disclosed, and the SX-682 has better antibacterial activity on staphylococcus aureus and can inhibit formation of biofilms including methicillin-sensitive staphylococcus aureus (MSSA) and methicillin-resistant staphylococcus aureus (MRSA). The SX-682 has no significant toxicity to human cytotoxicity in the bacteriostatic concentration range, and provides key support for subsequent anti-infection application of the SX-682.

The invention discloses an application of a hexagonal copper sulfide nano-platform with photo-thermal enhanced peroxidase activity in treatment of methicillin-resistant staphylococcus aureus infection so as to promote healing of infected wounds. An improved one-pot method is adopted to synthesize a hexagonal copper sulfide nano-sheet. Due to the fact that the hexagonal copper sulfide nanosheet shows good photothermal conversion efficiency and photothermal stability in a second near-infrared window and further shows excellent peroxidase-like activity, temperature rise caused by the photothermal effect of the hexagonal copper sulfide nanosheet remarkably amplifies the peroxidase-like activity of the hexagonal copper sulfide nanosheet. The hexagonal copper sulfide nanosheet plays a good biological catalytic antibacterial role in vitro, under photo-thermal irradiation, abscess fading and healing of in-vivo methicillin-resistant staphylococcus aureus infected wounds are promoted, and toxicity can be ignored. The copper sulfide nanosheet provides a feasible strategy for effectively treating a deep methicillin-resistant staphylococcus aureus infected wound by utilizing a synergistic treatment platform.

The invention discloses an application of idebenone in preparation of an antibacterial product. According to the invention, the in-vitro antibacterial activity and antibacterial spectrum of idebenone on clinical common strains are researched, and the research result shows that idebenone has an inhibiting effect on the growth of staphylococcus aureus. When the concentration of idebenone is within the range of 32-128 mu g / mL, growth of drug-resistant and sensitive staphylococcus aureus can be remarkably inhibited. Therefore, idebenone can be used for treating staphylococcus aureus infection and can be used for preparing antibacterial products.

The invention relates to the technical field of nano-medicine carriers, in particular to composite drug-loaded nanoparticles based on acylated polysaccharide and berberine as well as a preparation method and application of the composite drug-loaded nanoparticles. The preparation method comprises the following steps: carrying out acylation modification on natural polysaccharide by using a basic catalyst and acid anhydride to obtain acylated natural polysaccharide; wherein the acylation modification mode comprises acetylation modification or propionylation modification; in an organic solvent, the berberine and the acylated natural polysaccharide are subjected to encapsulation treatment, and the composite drug-loaded nanoparticles based on the acylated polysaccharide and the berberine are obtained. According to the preparation method, the natural polysaccharide is subjected to acylation modification, the hydrophobicity of the natural polysaccharide is adjusted, and the encapsulation efficiency of berberine is remarkably improved. On one hand, the composite drug-loaded nanoparticles can significantly improve the bioavailability of berberine and prolong the in-vivo action time of berberine, and on the other hand, the composite drug-loaded nanoparticles can promote the repair and healing of wounds infected by staphylococcus aureus and reduce the drug resistance of staphylococcus aureus.

The application discloses an antibacterial peptide derived from the skin of bullfrog and application thereof, and the amino acid sequence of the antibacterial peptide is GSVGPVGPR (as shown in SEQ ID NO:1), and the molecular weight is 824.4504 g / mol. The antibacterial peptide has obvious inhibiting effect on Staphylococcus aureus, and can be used for preparing a medicine for preventing or inhibiting Staphylococcus aureus infection. Meanwhile, the antibacterial peptide and vitamin A have a significant synergistic bactericidal effect on Staphylococcus aureus. The antibacterial peptide and vitamin A can significantly reduce the use concentration of single component, improve the antibacterial efficiency, overcome the bacterial drug resistance problem, and can be used for preparing antibacterial medicines, skin external preparation, medical dressings, feed additives and food preservatives.

The application discloses an antibody-antibiotic conjugate and application thereof, and a structural formula of the antibody-antibiotic conjugate is shown as formula (I) and is composed of a payload antibiotic, a monoclonal antibody targeting Kdo monosaccharide and an enzyme-sensitive linker; the antibody-antibiotic conjugate has strong affinity to Kdo antigen and can be combined with Staphylococcus aureus of different serotypes. Enzymatic treatment of the antibody-antibiotic conjugate can release free antibiotics to improve the bactericidal efficiency on Staphylococcus aureus; the antibody-antibiotic conjugate can effectively kill intracellular bacteria which are difficult to be affected by traditional small-molecule antibiotics through the mediation of the antibody; in the application of a Staphylococcus aureus-induced mouse pneumonia and nephritis model, the antibody-antibiotic conjugate can effectively remove bacteria in the lung and kidney, and the therapeutic effect is better than that of vancomycin. Therefore, the antibody-antibiotic conjugate has potential application in the development of Staphylococcus aureus infection drugs.

The present invention discloses a Bacillus cereus aminomethyltransferase antimicrobial peptide BA14, whose amino acid sequence is HKKEMVLAWLQNQK, and the molecular weight of the antimicrobial peptide is 1753.092 Daltons. The antimicrobial peptide of the present invention has a significant inhibitory effect on Staphylococcus aureus, and can be used as a medicine or feed additive for preparing a drug for preventing or inhibiting Staphylococcus aureus infection. Studies have shown that the antimicrobial peptide BA14 of the present invention combined with vitamin D3 can kill or strongly inhibit the growth of Staphylococcus aureus.

The present invention discloses a fully human SEB monoclonal antibody against Staphylococcus aureus enterotoxin B and its applications. The amino acid sequences of CDR1, CDR2, and CDR3 in the variable region of the heavy chain of the antibody are shown as SEQ ID NO.5, SEQ ID NO.6, and SEQ ID NO.7 respectively; the amino acid sequences of CDR1, CDR2, and CDR3 in the variable region of the light chain are shown as SEQ ID NO.9, SEQ ID NO.10, and SEQ ID NO.11 respectively; the antibody can specifically bind to Staphylococcus aureus enterotoxin B and can be used for the treatment, prevention, or diagnosis of Staphylococcus aureus infections and toxic shock syndrome caused by enterotoxin B, which will become an important direction in the research field of "non-antibiotic" treatment of drug-resistant Staphylococcus aureus infections and control of the development of drug resistance.

The invention discloses a preparation method of a phenol derivative capable of effectively inhibiting staphylococcus aureus, and belongs to the technical field of synthesis and application of medical intermediates. The preparation method comprises the following steps: under the conditions of protective atmosphere and illumination, carrying out an addition reaction on 4-benzal-2, 6-di-tert-butylcyclohexane-2, 5-diene-1-ketone and cyclohexane under the action of 4-nitrophthalonitrile, so as to obtain the 2, 6-di-tert-butyl-4-(cyclohexyl (phenyl) methyl) phenol. The preparation method has the advantages of simplicity in operation, mild reaction conditions, low cost of used reagents, high yield and the like, is favorable for realizing large-scale production, provides a key intermediate support for developing low-cost and high-activity anti-staphylococcus aureus drugs, and has important significance in relieving clinical drug-resistant staphylococcus aureus infection treatment dilemma.

The present invention provides a use of an antimicrobial peptide in the preparation of a drug for resisting Staphylococcus aureus infection. In a pneumonia mouse model infected with Staphylococcus aureus, the therapeutic effect of GHb3K and GHbK4R is better than that of vancomycin, the inflammatory response can be significantly reduced, and the in vivo toxicity is lower than that of vancomycin. GHb3K and GHbR can significantly promote the healing of chronic infectious wounds of methicillin-resistant Staphylococcus aureus (MRSA), and the therapeutic effect is better than that of mupirocin ointment. The antimicrobial peptide provided by the present invention has the potential to be developed into a drug for treating pneumonia infected with Staphylococcus aureus and a drug for treating chronic wounds infected with MRSA.

The invention discloses an application of a photostable pyridine fused Norcorrole nickel (II) dimer in treatment of staphylococcus aureus infection, and belongs to the technical field of medicines. The efficient antibacterial performance of the anti-aromaticity compound Ni (II)-PyNc2 under NIR irradiation is proved, the PCE of the anti-aromaticity compound Ni (II)-PyNc2 reaches 73%, and the temperature rises to 56 DEG C after the anti-aromaticity compound Ni (II)-PyNc2 is irradiated for 6 minutes. Through in-vitro and in-vivo experiments, Ni (II)-PyNc2 shows excellent light stability, biological membrane inhibition capability and wound healing promotion effect, and has good biocompatibility. The material is expected to become an ideal candidate for clinical photo-thermal therapy.

The application belongs to the technical field of microorganisms, and discloses application of shikimic acid in preparation of antibacterial preparations for inhibiting staphyloxin synthesis. It is found that shikimic acid can inhibit synthesis of staphyloxin in methicillin-resistant Staphylococcus aureus (MRSA), reduce tolerance of the bacteria to oxidative stress, induce accumulation of intracellular active oxygen, and damage cell membrane structure and function, including reducing cell membrane order, inducing membrane depolarization, increasing membrane permeability, and leading to ATP leakage and energy metabolism disorder. A new strategy and preparation direction are provided for clinical treatment of multi-drug resistant Staphylococcus aureus infection, and the application has important theoretical value and application prospect.

The invention discloses a manganese-based nano-enzyme preparation method, a manganese-based nano-enzyme product and an application of the manganese-based nano-enzyme product in antibiosis, and belongs to the technical field of nano-enzymes and biomedicine nanotechnology. According to the preparation method, KMnO4 and C18H34O2 are used as raw materials, and the manganese-based nano-enzyme is prepared through a water phase method. The nano-enzyme shows good application prospects in removing bacterial biofilms, inhibiting bacteria from forming biofilms and treating wound infection models. Animal experiments show that the hydrogel has excellent biocompatibility, is free of toxic accumulation, and can effectively treat mouse wound staphylococcus aureus infection and promote wound healing.

The invention discloses a transgenic animal antibody high-yield expression system based on double-copy site-specific integration and application of the transgenic animal antibody high-yield expression system. According to the invention, dual-copy anti-staphylococcus aureus enterotoxin B (SEB) monoclonal antibody genes are integrated at safe sites of mouse ROSA26 and H11 in a targeting manner, so that the whole-body high-level stable expression of the antibody in a mouse body is realized, and the yield and neutralizing activity of the antitoxin antibody are remarkably improved. The invention provides a new thought and a new strategy for the development of a low-cost and high-efficiency therapeutic antibody bioreactor. Besides, the constructed SEB antibody gene animal model provides an important tool for research on staphylococcus aureus infection resistance, provides a potential model animal solution for disease prevention and control of animal husbandry, and has good application value and industrial transformation prospect.

The present invention discloses the use of ferrous ions in the preparation of products for treating bacterial infections, belonging to the field of medical technology. Ferrous ions were used in antibacterial activity tests on Staphylococcus aureus, demonstrating a strong bactericidal effect. When sterilizing Staphylococcus aureus, the survival rate was less than 0.001%, and when sterilizing methicillin-resistant Staphylococcus aureus (MRSA), the survival rate was less than 0.01%. The use of ferrous ion-containing hydrogels in the treatment of keratitis and skin wound infections significantly reduced the risk of MRSA lung infection and effectively and timely prevented the reproduction and spread of microorganisms in the body. This indicates that drugs containing ferrous compounds can be used to treat Staphylococcus aureus infections, including MRSA.